Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial (NCT04462406)
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients With Advanced Melanoma (PET-Stop)
🩺 Plain-English Summary (8th-Grade Level)
This phase II trial investigates how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be removed by surgery (unresectable). Anti-PD-1 therapy has become a standard therapy option for patients with unresectable melanoma. This trial is being done to determine if doctors can safely shorten the use of standard of care anti-PD1 therapy for melanoma by using biomarkers seen on PET/CT imaging and tumor biopsy.
Who can join: Review the eligibility criteria below.
Location: Thomas Hospital — Fairhope, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (482 Sites)
Showing the first 25 of 482 sites.
- Thomas Hospital — Fairhope, Alabama
- Mobile Infirmary Medical Center — Mobile, Alabama
- Fairbanks Memorial Hospital — Fairbanks, Alaska
- Cancer Center at Saint Joseph's — Phoenix, Arizona
- Banner University Medical Center - Tucson — Tucson, Arizona
- University of Arizona Cancer Center-North Campus — Tucson, Arizona
- Mercy Hospital Fort Smith — Fort Smith, Arkansas
- CHI Saint Vincent Cancer Center Hot Springs — Hot Springs, Arkansas
- CARTI Cancer Center — Little Rock, Arkansas
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- Mercy Cancer Center - Carmichael — Carmichael, California
- Mercy San Juan Medical Center — Carmichael, California
- Kaiser Permanente Dublin — Dublin, California
- Mercy Cancer Center - Elk Grove — Elk Grove, California
- Kaiser Permanente-Fremont — Fremont, California
- Fresno Cancer Center — Fresno, California
- Kaiser Permanente-Fresno — Fresno, California
- The Angeles Clinic and Research Institute - West Los Angeles Office — Los Angeles, California
- Cedars Sinai Medical Center — Los Angeles, California
- Mercy Cancer Center — Merced, California
- Kaiser Permanente-Modesto — Modesto, California
- Kaiser Permanente Oakland-Broadway — Oakland, California
- Kaiser Permanente-Oakland — Oakland, California
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Melanoma
- Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery — Birmingham, Alabama
- Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma — Mobile, Alabama
- A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma — Scottsdale, Arizona
- A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma — Pittsburgh, Pennsylvania
- Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors — St Louis, Missouri
Explore by condition: All Advanced Melanoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.